My research interests and active protocols include the following.

• 1976–1991
  Radiation Co-Chairman: Hematology, Radiation Therapy, New Agents and Pilot Studies, Biological Response Modifiers, Bone Marrow Transplantation and Audit Steering Committees, ECOG.
• 1991–present
  Member, Core Committees for Radiation Oncology, Bone Marrow Transplant,Lymphoma and Myeloma, ECOG.

Clinical Trials Experience

Eastern Cooperative Oncology Group

• Phase II Study Using Autologous Bone Marrow Transplantation as Consolidation Therapy for Patients With Diffuse Mixed and Diffuse Large Cell Non-Hodgkin's Lymphoma in Complete or Partial Remission After MACOP-B Chemotherapy. (EST P-E486)
• Phase II Study of ABMT of 4-HC Purged Marrow Followed by GM-CSF Infusions as Consolidation Therapy for Patients with Low-Grade Non-Hodgkin's Lymphoma. (EST P-C488)
• Phase II Trial Examining GM-CSF Infusions after Autologous Bone Marrow Transplantation for Relapsed or Refractory Non-Hodgkin's Lymphoma. (EST P-Z488)
• Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission (Intergroup Study). (E2993)
• A Randomized Phase III Trial to Evaluate High-Dose Sequential Chemotherapy and Peripheral Blood Stem Cell Autologous Transplantation(HDS) vs CHOP as Initial Therapy for Patients with Poor Risk Intermediate/High Grade Non-Hodgkin's Lymphoma. (E2493)
• Phase III Intergroup Study of Standard Dose versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma.(S9321)

Mayo Clinic

• High Dose Chemotherapy and Total Body Radiation with Peripheral Blood Stem Cell Reconstitution for Patients With Relapsing or Refractory Multiple Myeloma. (88-80-01)
• High-Dose Chemotherapy and Total Body Radiation with Peripheral Blood Stem Cell Reconstitution for Patients with Relapsing Multiple Myeloma. 3. 95-80-02 High Dose Melphalan Chemotherapy and Total Body Irradiation with Peripheral Blood Stem Cell Reconstitution for Patients with Primary Systemic Amyloidosis. (92-80-03)